Today: 8 June 2026
Browse Category

NASDAQ:BEAM 20 October 2025 - 4 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics stock rises 5% after BofA lifts target to $45

Beam Therapeutics shares rose about 5% to $28.24 by early afternoon Tuesday after Bank of America raised its price target to $45 and reaffirmed a buy rating. The stock touched $30.49 before paring gains. A new SEC filing showed Chief Legal Officer Christine Bellon sold 1,254 shares on Dec. 31 in an automatic transaction tied to tax withholding.
6 January 2026
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

ARK Invest bought 521,867 Pinterest shares across three funds after the stock fell over 20% on weak holiday-quarter guidance. The firm also added CRISPR Therapeutics and Beam Therapeutics shares earlier in the week. ARK sold 105,576 Roku shares and 56,095 Robinhood shares, and reduced its position in Teradyne. Pinterest projected Q4 revenue below consensus, citing softer ad spending and tougher competition.
6 November 2025
········
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics shares rose about 17% to $30 after the FDA granted RMAT and Orphan Drug designations to its lead gene-editing programs, BEAM-101 and BEAM-302. Early trial data showed BEAM-302 raised protective AAT levels and BEAM-101 produced durable increases in fetal hemoglobin. Wall Street’s average 12-month price target is $45–46, implying roughly 70–80% upside.
21 October 2025
··
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····

Stock Market Today

  • Intesa Sanpaolo Sells 1000 MPS Shares at EUR 9.95 on Euronext Milan
    June 8, 2026, 3:20 PM EDT. Intesa Sanpaolo sold 1000 shares of Monte dei Paschi di Siena (MPS) on Euronext Milan for EUR 9.95 per share on June 8, 2026. The transaction reflects strategic asset adjustments by the Italian banking group amid market conditions. MPS shares trade on Euronext Milan, Italy's main stock exchange. This move could influence investor sentiment on both institutions.

Latest articles

Galaxy Digital spikes 24% as investors look at AI data center plans

Galaxy Digital spikes 24% as investors look at AI data center plans

8 June 2026
Galaxy Digital shares soared 23.6% to $31.07 after CEO Mike Novogratz said its West Texas AI data center—half of which is already leased—now represents more than half the company’s value, shifting focus from crypto to AI infrastructure; the stock’s surge outpaced bitcoin’s 2.7% rise as investors repriced Galaxy’s data-center business amid execution risks and strong analyst buy ratings.
Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

8 June 2026
Nu Holdings shares slid 3.1% to $11.60 as investors weighed CFO transition risks and rising credit costs, erasing last week’s 4.1% buyback-driven bounce; BofA downgraded the stock to Underperform with a $10 target, citing uncertainty from Lago’s exit, while Nu’s $1B buyback failed to stem a 10.7% weekly drop and 30.7% year-to-date decline, leaving shares just above their 52-week low.
Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

8 June 2026
Inno Holdings shares soared twentyfold to $20.97 after announcing a $3 million AI sales agent deal for its used mobile phone business, but investor risks remain with a recent $60 million at-the-market stock program and ongoing going-concern warnings in filings, as the project is still in early development and not yet commercially launched.
Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

8 June 2026
Emirates slashed June A380 flights on 10 major routes as soaring fuel costs and Middle East airspace disruption forced airlines to cut capacity, prompting IATA to halve its 2026 global profit forecast to $23 billion from $41 billion, with industry-wide seat reductions and rising fares expected as carriers struggle to absorb shocks during peak travel.
Wall Street Watches Microsoft’s $37 Billion AI Bet

Wall Street Watches Microsoft’s $37 Billion AI Bet

8 June 2026
Microsoft shares fell 1.5% to $410.30 as investors weighed bullish analyst calls and NHS England’s Copilot rollout against concerns that surging AI revenue—now at a $37 billion run rate—may not outpace rising costs and margin pressure from heavy infrastructure investment.
Go toTop